Ziarco recently announced the closing of an initial $6-million tranche of Series A financing totalling $27 million. The round was led by Biotechnology Value Fund L.P, with participation by Pfizer Venture Investments.

Concurrent with the financing, Ziarco has entered into an agreement with Pfizer Inc. for the exclusive worldwide rights to commercialize a portfolio of clinical, preclinical, and research anti-inflammatory and anti-allergic assets. In return, Pfizer will receive equity as well as certain product-based milestone and royalty payments.

 » Read more about: Ziarco Pharma Acquires Pfizer Drugs, Secures Financing  »